These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 19954478)

  • 1. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H
    Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
    Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
    Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
    Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
    Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
    Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
    Yamagishi S
    Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
    Park L; Raman KG; Lee KJ; Lu Y; Ferran LJ; Chow WS; Stern D; Schmidt AM
    Nat Med; 1998 Sep; 4(9):1025-31. PubMed ID: 9734395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
    Rojas A; Morales MA
    Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE biology, atherosclerosis and diabetes.
    Barlovic DP; Soro-Paavonen A; Jandeleit-Dahm KA
    Clin Sci (Lond); 2011 Jul; 121(2):43-55. PubMed ID: 21457145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGE, RAGE, and ROS in diabetic nephropathy.
    Tan AL; Forbes JM; Cooper ME
    Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
    Kanková K
    Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K; Watson A; Soro-Paavonen A
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications.
    Chawla D; Bansal S; Banerjee BD; Madhu SV; Kalra OP; Tripathi AK
    Microvasc Res; 2014 Sep; 95():1-6. PubMed ID: 24984291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end products: sparking the development of diabetic vascular injury.
    Goldin A; Beckman JA; Schmidt AM; Creager MA
    Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.